DOJ’s April 2026 Cannabis Order: What It Does and What It Does Not Do

This week, the U.S. Department of Justice issued a final order, effective April 22, 2026, placing Food and Drug Administration (FDA)-approved drug products containing marijuana, as well as marijuana covered by a state-issued medical marijuana license, into Schedule III of the Controlled Substances Act (CSA). The development is meaningful for industry participants. It is not transformative. As with prior federal actions in this space, the practical impact depends heavily on the details and on... By: Sheppard, Mullin, Richter & Hampton LLP